(BRM) BioRem - Ratings and Ratios

Exchange: V • Country: Canada • Currency: CAD • Type: Common Stock • ISIN: CA09068G1046

BRM: Biofilters, Biotrickling Filters, Air Filtration

BioRem Inc. (V:BRM) is a clean technology engineering firm specializing in the design, manufacture, distribution, and sale of advanced air pollution control systems. These systems are engineered to effectively eliminate odors, volatile organic compounds (VOCs), and hazardous air pollutants (HAPs) across various industrial and commercial applications. The companys product portfolio includes biofilters, biotrickling filters, multi-stage synergy systems, biogas desulfurization systems, dry scrubber adsorption systems, and cannabis odor control systems. Its solutions are marketed under the BIOSORBENS, XLD, BIOPAK, BIOROLL, and BIOBLOK brands. With operations spanning Canada, the United States, China, and other international markets, BioRem Inc. has established itself as a key player in the air pollution control sector. Founded in 1990, the company is headquartered in Puslinch, Canada, and is recognized for its expertise in delivering environmentally friendly and cost-effective solutions to industrial emissions challenges.

Based on the provided data, here is a 3-month forecast for BioRem Inc. (V:BRM):

Over the next three months, BRM is expected to experience a period of consolidation. The stock is currently trading below its 20-day (2.66) and 50-day (2.84) moving averages, indicating bearish momentum in the short term. However, the 200-day moving average (2.50) suggests long-term support near current levels. The Average True Range (ATR) of 0.17 indicates low volatility, which may limit significant price movements in either direction.

From a fundamental perspective, BRMs forward P/E ratio of 12.77 suggests that the market expects earnings growth, despite the current P/E of 10.14. The high price-to-book (P/B) ratio of 4.46 reflects investor confidence in the companys intangible assets and growth prospects. With a return on equity (RoE) of 52.26, BRM demonstrates strong profitability relative to shareholder equity. The price-to-sales (P/S) ratio of 1.05 indicates a reasonable valuation given its revenue streams. These metrics collectively point to a stable financial foundation, which may support a rebound in the stock price as market sentiment improves.

Additional Sources for BRM Stock

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

BRM Stock Overview

Market Cap in USD 33m
Sector Industrials
Industry Pollution & Treatment Controls
GiC Sub-Industry Industrial Machinery & Supplies & Components
IPO / Inception

BRM Stock Ratings

Growth 5y 90.9%
Fundamental 75.0%
Dividend 0.0%
Rel. Strength 45.4
Analysts -
Fair Price Momentum 2.46 CAD
Fair Price DCF 7.56 CAD

BRM Dividends

No Dividends Paid

BRM Growth Ratios

Growth Correlation 3m -88.8%
Growth Correlation 12m 73.8%
Growth Correlation 5y 94.1%
CAGR 5y 43.10%
CAGR/Max DD 5y 1.04
Sharpe Ratio 12m -0.99
Alpha 4.34
Beta 0.851
Volatility 133.56%
Current Volume 90.1k
Average Volume 20d 27.7k
What is the price of BRM stocks?
As of April 11, 2025, the stock is trading at CAD 2.10 with a total of 90,076 shares traded.
Over the past week, the price has changed by -8.70%, over one month by -16.00%, over three months by -31.60% and over the past year by +46.85%.
Is BioRem a good stock to buy?
Yes, based on ValueRay Fundamental Analyses, BioRem (V:BRM) is currently (April 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 75.01 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BRM as of April 2025 is 2.46. This means that BRM is currently undervalued and has a potential upside of +17.14% (Margin of Safety).
Is BRM a buy, sell or hold?
BioRem has no consensus analysts rating.
What are the forecast for BRM stock price target?
According to ValueRays Forecast Model, BRM BioRem will be worth about 2.7 in April 2026. The stock is currently trading at 2.10. This means that the stock has a potential upside of +29.05%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 2.7 29%